These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12270732)

  • 1. Molecular mechanisms of B-lymphocyte transformation by Epstein-Barr virus.
    Bishop GA; Busch LK
    Microbes Infect; 2002 Jul; 4(8):853-7. PubMed ID: 12270732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus: 40 years on.
    Young LS; Rickinson AB
    Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cells under influence: transformation of B cells by Epstein-Barr virus.
    Küppers R
    Nat Rev Immunol; 2003 Oct; 3(10):801-12. PubMed ID: 14523386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of B-Cell Oncogenesis Induced by Epstein-Barr Virus.
    Saha A; Robertson ES
    J Virol; 2019 Jul; 93(13):. PubMed ID: 30971472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell transformation induced by Epstein-Barr virus--living dangerously.
    Rowe M
    Semin Cancer Biol; 2001 Dec; 11(6):403-5. PubMed ID: 11669601
    [No Abstract]   [Full Text] [Related]  

  • 7. Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors.
    Chen X; Kamranvar SA; Masucci MG
    Oncogene; 2016 Jul; 35(29):3807-16. PubMed ID: 26592445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.
    Saha A; Robertson ES
    Clin Cancer Res; 2011 May; 17(10):3056-63. PubMed ID: 21372216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dithiocarbamates and viral IL-10 collaborate in the immortalization and evasion of immune response in EBV-infected human B lymphocytes.
    Irons RD; Le AT
    Chem Biol Interact; 2008 Mar; 172(1):81-92. PubMed ID: 18163983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses.
    Lacoste V; Judde JG; Bestett G; Cadranel J; Antoine M; Valensi F; Delabesse E; Macintyre E; Gessain A
    Leuk Lymphoma; 2000 Jul; 38(3-4):401-9. PubMed ID: 10830748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Trends and Alternative Scenarios in EBV Research.
    Minarovits J; Niller HH
    Methods Mol Biol; 2017; 1532():1-32. PubMed ID: 27873264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
    Aguirre AJ; Robertson ES
    J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
    Tanner JE; Alfieri C
    Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin's lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules.
    Kasprzak A; Spachacz R; Wachowiak J; Stefanska K; Zabel M
    Folia Histochem Cytobiol; 2007; 45(3):169-79. PubMed ID: 17951165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF-κB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas.
    Vento-Tormo R; Rodríguez-Ubreva J; Lisio LD; Islam AB; Urquiza JM; Hernando H; López-Bigas N; Shannon-Lowe C; Martínez N; Montes-Moreno S; Piris MA; Ballestar E
    Nucleic Acids Res; 2014; 42(17):11025-39. PubMed ID: 25200074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.
    Miyauchi K; Urano E; Yoshiyama H; Komano J
    Cancer Sci; 2011 Jun; 102(6):1236-41. PubMed ID: 21392167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth.
    Shannon-Lowe C; Baldwin G; Feederle R; Bell A; Rickinson A; Delecluse HJ
    J Gen Virol; 2005 Nov; 86(Pt 11):3009-3019. PubMed ID: 16227222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas.
    Finberg RW
    Curr Opin Oncol; 2001 Sep; 13(5):349-53. PubMed ID: 11555711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis.
    Price AM; Luftig MA
    PLoS Pathog; 2015 Mar; 11(3):e1004656. PubMed ID: 25790223
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.